ERBB2 and gastric cancer: This phase 3, open-label, randomised controlled trial, which showed a median overall survival of 13.8 months in the trastuzumab plus chemotherapy group compared to 11.1 months in the chemotherapy-alone group, established trastuzumab in combination with chemotherapy as the first-line treatment for HER2-positive advanced GC [15, 16].